Not cost-effective at zero price: valuing and paying for combination therapies in cancer

Expert Rev Pharmacoecon Outcomes Res. 2021 Jun;21(3):331-333. doi: 10.1080/14737167.2021.1879644. Epub 2021 Feb 9.

Authors

Nicholas R Latimer¹, Adrian Towse², Chris Henshall²

Affiliations

¹ Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK.
² Office of Health Economics, London, UK.

PMID: 33472440
DOI: 10.1080/14737167.2021.1879644

No abstract available

Keywords: Cancer; combination therapy; cost-effectiveness; costs; economic evaluation; value-based pricing.

Publication types

Editorial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / economics
Cost-Benefit Analysis
Drug Costs
Humans
Neoplasms / drug therapy*
Neoplasms / economics
Technology Assessment, Biomedical